Neurotech Pharmaceuticals Appoints Scott Hunter as Chief Commercial Officer

Neurotech Pharmaceuticals announced the expansion of its executive team with the appointment of Scott Hunter as Chief Commercial Officer bringing two decades of eye care experience across both rare disease and specialty markets.

“Scott’s appointment as the company’s first Chief Commercial Officer marks an important milestone for Neurotech. Scott will be instrumental in helping us develop the commercial strategy and establish our commercial infrastructure,” Richard Small, Chief Executive Officer of Neurotech, said in a company news release. “His proven success of bringing products to market that address unmet needs is a perfect fit with our vision and culture, which is dedicated to slowing disease progression while helping patients maintain vision and quality of life.”

“I am extremely excited to join the Neurotech team and build the commercial organization,” said Mr. Hunter. “Starting with science behind NT-501, I believe Neurotech can drastically change the management of sight-threatening retinal conditions such as MacTel.”

Mr. Hunter most recently worked at Novartis where he was the Global Marketing Head for Luxturna (voretigene neparvovec-rzyl), responsible for advancing the global strategy for the first commercially approved ocular gene therapy. Before Novartis, Mr. Hunter was at Shire, where he was instrumental in the build-out of the US ophthalmics franchise and launch of Xiidra, culminating in the divestiture to Novartis for up to $5.3 billion. Prior to that, he spent 12 years at Bausch & Lomb, where he held roles of increasing responsibility across research and development (R&D) and marketing. He earned his M.S. in Pharmacoeconomics from the University of Florida and his MBA from the University of Tampa after completing his B.S. in Biology at the University of South Florida.